iosBio has ongoing collaborations with a number of pharmaceutical companies:
- GSK: iosBio has entered into an option and license agreement with GSK to evaluate the company’s thermal stability platform technology
- Zoetis: Zoetis (formerly Pfizer Animal Health) and iosBio entered a three-year collaboration to explore the potential of the company’s technologies in biopharmaceuticals and vaccines for animals
- Oncolytic biotech [confidential]: iosBio entered into an option and license agreement with a confidential oncolytic biotech company to stabilize their lead clinical asset
iosBio seeks further partnership opportunities with pharma and biotech companies on:
- iosBio’s internal pipeline
- Therm-SB: providing thermal stability to partners assets (vaccines, vectors, viruses)
- OraPro: efficaciously delivering partners vectors to the GI tract to transduce DNA products for host cells
Please contact [contact details]